BioDelivery Sciences International, Inc. announced the closing of its previously announced agreement with Endo Pharmaceuticals, Inc. (Endo) terminating Endo's licensing of rights for BELBUCA® (buprenorphine) buccal film (CIII). As a result of the closing, the worldwide rights to BELBUCA have now been transferred back to BDSI.
1st Jan change | Capi. | |
---|---|---|
+131.89% | 7.71B | |
+2.67% | 987M | |
+46.93% | 961M | |
+2.39% | 668M | |
-.--% | 600M | |
-3.05% | 582M | |
+10.28% | 536M | |
-.--% | 500M | |
+3.47% | 470M |